Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study.

BACKGROUND

Multiple Myeloma (MM) is a complex hematologic malignancy with a rapidly evolving therapeutic landscape. Real-world data on treatment regimen use beyond the first line in China are limited.

METHODS

We analyzed data from the CancerMPact Treatment Architecture database, based on a 2024 survey of 120 Chinese physicians regarding management and treatment durations for relapsed/refractory MM. Descriptive statistics summarized regimen selection and duration across second and later lines.

RESULTS

Substantial heterogeneity in regimen selection was observed, with no single regimen used in more than 10% of patients across all treatment lines. In second line, 66.3% of patients received a bortezomib-based, daratumumab-based, or daratumumab plus bortezomib-based regimen. Common second-line regimens and time of utilization included carfilzomib, pomalidomide, dexamethasone (9.6%; 9.2 months), daratumumab, bortezomib, dexamethasone (9.0%; 8.1 months), and daratumumab, bortezomib, lenalidomide, dexamethasone (7.6%; 7.7 months). In third line, top regimens were carfilzomib, pomalidomide, dexamethasone (9.0%; 7.3 months), daratumumab, carfilzomib, dexamethasone (8.2%; 8.3 months), and daratumumab, bortezomib, lenalidomide, dexamethasone (7.1%; 8.1 months). Novel agents and chimeric antigen receptor (CAR)-T cell therapies saw increased use in later lines.

CONCLUSION

Real-world management of relapsed/refractory MM in China is highly variable. These findings highlight the necessity for ongoing research and evidence-based guidelines to optimize patient outcomes.